euro-infectious-diseases-histopathology-2018-posters

32 / 33

Volume 4 Journal of Infectious Diseases and Treatment
ISSN: 2472-1093
Page 68
Euro Infectious Diseases 2018 &
Histopathology 2018
September 27-29, 2018
&
JOINT EVENT
September 27-29, 2018 Rome, Italy
5th International Conference on Histopathology & Cytopathology
10th Euro-Global Conference on Infectious Diseases
Predictors used to assess virological response to direct acting anti-HCV therapy
Refa't A Sadeq1, Nagi M Shafik2 and Mona R Sadeq3
1Port Said University, Egypt
2WHO, Egypt
3Mansoura University, Egypt
Hepatitis C is an infectious disease affecting primarily the liver, caused by the hepatitis C virus (HCV). HCV infection is a
major problem in Egypt. Egypt has the highest prevalence of the Hepatitis C virus (HCV) in the world, with 14 percent of
the population infected and 11.8 million patients, according to the World Health Organization. Every year there are 170,000-
200,000 new HCV cases in Egypt. It was first discovered in 1989. HCV is a small, enveloped, single-stranded, positive-sense
RNA virus. It is a member of the Hepacivirus genus in the family Flaviviridae. There are seven major genotypes of HCV, which
are known as genotypes one to seven . It is transmitted by injection which means spread primarily by blood-to-blood contact
associated with intravenous drug use, poorly-sterilized medical equipment, and transfusions. Aim of the study: This study
aims to determine the common prevalent HCV genotypes among chronic HCV patients in Egypt and to evaluate the rate of
sustained virological response (SVR) with some factors that affecting it. Subject & Methods: In our study fifty patients were
enrolled. Eligible participants were aged ≥18 years, had chronic HCV genotype 4 infection (serum HCV RNA≥2000 IU/mL).
All Biochemical tests for liver function, Blood sugar and HBA1C were done for all cases. The recommended regimen was
DCV 60 mg plus SOF 400 mg once daily for 12 weeks; at their discretion, physicians could add RBV to the regimen or reduce
treatment duration. HCV-RNA (viral load) was measured using RT-PCR (quantitative method) (Qiagen/BDCompany) (Before
treatment & After 12 weeks) and serum Neopterin ELISA kit. Results: SVR achieved 12 weeks after the end of treatment. Of
the 50 evaluable patients, 6 received DCV+SOF and 44 DCV+SOF+RBV. Most patients were men (76%). SVR12 (modified
intention-to-treat) was achieved by 98% of patients (48/50); 1 patient had virological breakthrough (was lost to follow-up at 4
weeks after treatment) and 1 patient was Non-responder. There was no statistically significant difference in treatment efficacy
between treatment-naive patients (100%, 37 of 37) and those with treatment experience (84.6%; 11 of 13) (P=.51). High SVR12
was observed regardless cirrhosis. There was a reduction in the mean neopterin level in patients after treatment in comparison
to pre-treatment level; however this reduction didn't reach a statistical significant value. Conclusions: In our study, the most
predominant genotype was genotype IV with 86%. Of our HCV-treated patients, had high SVR. HCV genotype-4, and low
baseline viral load were predictive of SVR.
J Infec Dis Treat 2018, Volume 4
DOI: 10.21767/2472-1093-C1-003